Article Text

Download PDFPDF
Acute rheumatic fever in the province of Manitoba, Canada, before and after the coronavirus (COVID-19) pandemic
  1. Kayla Edison1,
  2. Dion Pepelassis1,2,
  3. Reeni Soni1,2,
  4. Daryl Schantz1,2,
  5. Ilan Buffo1,2
  1. 1 Pediatrics, University of Manitoba, Winnipeg, Manitoba, Canada
  2. 2 Pediatric Cardiology, Shared Health, Winnipeg, Manitoba, Canada
  1. Correspondence to Dr Kayla Edison, Pediatrics, University of Manitoba, Winnipeg, Canada, R3A1S1; kedison{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The COVID-19 pandemic came with strict public health guidelines for social distancing and infection control measures. Schools and daycare centres were closed for significant periods of time. The consequences of these measures for the epidemiology of transmissible paediatric disease are still unfolding. However, data 2 years into the pandemic indicate there has been a decrease in the incidence of at least one of the two most common causes of acquired heart disease in children, Kawasaki disease (KD). Japan, Korea, Singapore and Taiwan all reported decreased incidence of KD from 2020 to 2021.1–3 To the best of our knowledge, there have been limited and conflicting data published on the other most common cause of acquired heart disease in children, acute rheumatic fever (ARF). A major referral centre in Turkey reported decrease from 28 new cases of ARF in 2016–2017 to only 2 cases …

View Full Text


  • Handling editor Josef S Smolen

  • Contributors KE and DP conceived the idea and wrote the letter. DP, RS, DS and IB completed cardiac assessments and interpreted investigations for diagnosis of both KD and ARF from 2018 to 2022 and reviewed the letter.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; externally peer reviewed.